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Abstract
The classical renin-angiotensin system (RAS) consists of enzymes and peptides that regulate blood pressure and electrolyte 
and fluid homeostasis. Angiotensin II (Ang II) is one of the most important and extensively studied components of the RAS. 
The beneficial effects of angiotensin-converting enzyme (ACE) inhibitors in the treatment of hypertension and heart failure, 
among other diseases, are well known. However, it has been reported that patients chronically treated with effective doses of 
these inhibitors do not show suppression of Ang II formation, suggesting the involvement of pathways alternative to ACE in 
the generation of Ang II. Moreover, the finding that the concentration of Ang II is preserved in the kidney, heart and lungs of 
mice with an ACE deletion indicates the important role of alternative pathways under basal conditions to maintain the levels of 
Ang II. Our group has characterized the serine protease elastase-2 as an alternative pathway for Ang II generation from Ang I 
in rats. A role for elastase-2 in the cardiovascular system was suggested by studies performed in heart and conductance and 
resistance vessels of normotensive and spontaneously hypertensive rats. This mini-review will highlight the pharmacological 
aspects of the RAS, emphasizing the role of elastase-2, an alternative pathway for Ang II generation.
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Renin-angiotensin system 
It is well established that the main end-product of the 
renin-angiotensin system (RAS), angiotensin II (Ang II), 
plays a key role in regulating cardiovascular homeostasis, 
acting both on the regulation of blood volume and peripheral 
vascular resistance (1). In recent years, however, several 
studies have shown that the RAS presents a much greater 
complexity than previously thought. Many peptides that were 
considered to be inactive metabolites had their biological 
activity recognized. Angiotensin III (Ang III), which is formed 
from Ang II by the action of aminopeptidase A, induces 
aldosterone release (2). Angiotensin IV (Ang IV), formed 
from Ang III by aminopeptidase N, has an important role in 
the central nervous system, especially related to memory, 
and also displays proliferative effects (3). Angiotensin 1-7 
(Ang-(1-7)), via activation of the MAS receptor, seems to 
have effects opposite to those mediated by Ang II. Another 
carboxypeptidase homologous to angiotensin-converting 
enzyme (ACE), called ACE-2, was simultaneously identi-
fied by two groups (4,5). ACE-2 cleaves Ang I and Ang 
II to generate Ang-(1-9) and Ang-(1-7), respectively. It is 
important to note that so far no direct biological activity for 
the Ang-(1-9) fragment was described, and it is suggested 
that this peptide can compete with Ang I by binding the 
active site of ACE, which then generates Ang-(1-7) from 
Ang-(1-9) (Figure 1).
The effects of the angiotensin peptides are exerted 
via activation of different angiotensin receptors, such as 
type 1 (AT1), type 2 (AT2), type 4 (AT4), and MAS (1). AT1 
receptors are expressed in the lungs, liver, kidney, heart, 
blood vessels, brain, adrenal glands, and various endocrine 
glands (6), and are activated by Ang II. AT1 receptors can 
also be stimulated by other mediators of the RAS with lower 
binding affinity, such as Ang III, Ang IV, and Ang-(1-7). AT2 
receptors are predominantly expressed in fetal tissues (a 
situation reversed after birth), and are also expressed in 
situations of injury. Ang II and Ang-(1-7) are ligands for 
the AT2 receptors whose activation leads to vasodilation 
and anti-proliferative effects. AT2-induced effects seem to 
antagonize the effects induced by AT1 activation (7). Ang 
IV binds to the AT4 receptor that is located in the brain, 
heart, lungs, liver, and kidneys, being related to cognitive 
functions and proliferative effects (8,9). The MAS receptor 
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is activated by Ang-(1-7), inducing vasodilation and anti-
proliferative effects (10).
ACE inhibitors are widely used not only in the treatment 
of hypertension, but also in other cardiovascular diseases 
(or diseases related to them) such as heart failure, myo-
cardial infarction, renal failure, and diabetic nephropathy 
(11). Results of numerous clinical studies (12,13) have 
established that blockade of the RAS with ACE inhibitors 
results in significant reduction of mortality in patients with 
heart failure or post-myocardial infarction. Since the benefits 
for survival were demonstrated with different ACE inhibitors, 
and all have common mechanisms, this important effect is 
attributed to ACE inhibition. Pharmacological studies show 
that ACE inhibitors may differ in their affinity for tissue ACE, 
but the clinical significance of this observation remains to 
be demonstrated (11).
In the last decade, evidence has accumulated showing 
that Ang II acts as a circulating hormone, and may also be 
formed locally in various tissues, acting as an autocrine 
or paracrine hormone and inducing a broad spectrum of 
effects on the cardiovascular and renal systems (14,15). 
Although the beneficial effects of the use of ACE inhibitors 
in the treatment of hypertension and heart failure, among 
other diseases, are well known, it has been reported that 
patients chronically treated with effective doses of these in-
hibitors do not show suppression of Ang II formation (16,17), 
suggesting the involvement of alternative pathways for Ang 
II generation. Moreover, the finding that the concentration 
of Ang II is maintained in the kidney, heart and lungs of 
mice with ACE deletion (18) indicates an important role 
of alternative pathways to maintain basal 
levels of Ang II.
Alternative pathways for Ang II 
generation
Several studies have shown the involve-
ment of other enzymes, in addition to ACE, 
in the generation of Ang II (19-21). The first 
descriptions of an alternative pathway for 
Ang II formation were reported by Boucher 
et al. (22) in the submandibular glands of 
rats, by Cornish et al. (23) in the hamster 
cheek, and by Trachte and Lefer (24) in 
the cat cardiac papillary muscle. Cornish 
et al. (23) demonstrated that the vasocon-
strictor response induced by Ang I in blood 
vessels of the hamster cheek pouch was 
only partially blocked by ACE inhibitors 
but completely abolished by Ang II recep-
tor antagonists, leading to the conclusion 
that this vascular bed converts significant 
amounts of Ang I to Ang II by a route that 
does not involve ACE. Cornish et al. (25) 
also observed the formation of Ang II in-
dependently of ACE in the coronary artery of hamsters. 
Some years later, Okunishi et al. (26) identified an Ang 
II-generating enzyme in dog mesenteric artery, which was 
sensitive to chymostatin and insensitive to ACE inhibitors. 
Urata et al. (27) demonstrated in vitro two pathways for the 
formation of Ang II in homogenates of human heart. These 
investigators observed that approximately 80% of the total 
formation of Ang II was associated with the presence of an 
unknown serine protease, whereas ACE-dependent Ang II 
generation was only responsible for approximately 11% of 
total Ang II. This cardiac serine protease was purified and 
identified as a new member of the chymase family, and 
was named human heart chymase (28). 
Although several enzymes can produce Ang II in vitro 
through cleavage of the Phe8-His9 bond of Ang I, their in 
vivo activity cannot be demonstrated. Moreover, some of 
these enzymes, such as trypsin, chymotrypsin and rodent 
chymases, also degrade Ang II (29). Data generated from 
the susceptibility of these different enzymes to protease 
inhibitors have allowed the classification of Ang II-forming 
enzymes into three categories (30). The first category cor-
responds to metallodipeptidyl carboxypeptidase known as 
ACE. The second category comprises the aprotinin-sensitive 
serine proteases, such as kallikrein (31), trypsin (30), tonin 
(22), and cathepsin G (32). The third category includes 
a group of chymostatin-sensitive serine proteases, such 
as the chymostatin-sensitive Ang II-generating enzyme 
found in the dog mesenteric artery (33), human chymase 
(27,28) and the rat elastase-2 enzyme (34,35). These two 
chymostatin-sensitive serine proteases, human chymase 
Figure 1. Representative peptides, enzymes, and receptors of the renin-angio-
tensin system. ANG = angiotensin; ACE = angiotensin-converting enzyme; ACE-
2 = angiotensin-converting enzyme-2; APA = aminopeptidase A; APN = amino-
peptidase N.
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and rat elastase-2, have been well characterized as ACE-
independent pathways for Ang II formation in vascular 
tissue (36-39). 
Despite the different characteristics of chymases in 
different species, these enzymes are functionally relevant 
in the ACE-independent formation of Ang II (33,40,41). 
The determination of distinct functional activities for ACE 
and chymases has been possible in some cases by the 
use of selective inhibitors (42) and substrates (43). The 
development of the compound Z-Ile-Glu-Pro-Phe-CO2H 
(CH5450), a peptide inhibitor of human heart chymase (42), 
provided an important pharmacological tool to investigate 
the enzymes responsible for tissue Ang II formation (41). 
Evidence that enzymatic ACE-independent pathways are 
functional in the conversion of precursors of circulating 
Ang II was provided by in vivo experiments (43-47) using 
the synthetic peptide [D-Pro11-Ala12]-Ang I. This biologi-
cally inactive Ang II precursor selectively releases Ang II 
after incubation with human chymase, but not with ACE or 
carboxypeptidases (43). This substrate has been used as 
a tool to demonstrate the role of chymases in the formation 
of Ang II in preparations derived from human tissues (41), 
primates (43,44), hamsters (46), dogs (48), cats (45), and 
even rats (47), a species that lacks chymase-dependent 
Ang II-forming activity. 
The chymases are described as an alter-
native pathway to ACE for Ang II generation. 
However, depending on the species studied, 
chymase may be generating or degrading 
Ang II. Kunori et al. (49) showed that the 
kinetics of Ang II formation by chymases 
from different species followed the order dog 
> human > hamster > mouse > rat (Kcat/km: 
18, 11, 0.69, 0.059, 0.0030 mM/min, respec-
tively), whereas the Ang II-degrading activity 
of chymases is: hamster > rat > mouse > 
dog (Kcat/km: 5.4, 4.8, 0.39, 0.29 mM/min, 
respectively), indicating that human chymase 
has only Ang II-generating activity, whereas 
rat chymase exhibits Ang II-degrading ac-
tivity. We have recently described a serine 
protease, a member of the chymotrypsin-like 
elastase family, named elastase 2A, which is 
secreted in the rat mesenteric arterial bed and 
features Ang II-forming activity (34,38). 
Rat elastase-2
We demonstrated the existence of some 
peptidases in the perfusate of the isolated 
rat mesenteric bed (50). The recirculating 
perfusion solution accumulated endo- and 
exo-soluble peptidases, among which a 
serine protease insensitive to captopril and 
capable to form Ang II from Ang I was iden-
tified. Later, this Ang II-forming serine protease of the rat 
mesenteric arterial bed perfusate was isolated and purified 
by a combination of filtration and affinity chromatography 
(34). The enzyme was sensitive to chymostatin and was 
identified as a glycoprotein with a molecular mass of 28.5 
kDa. The amino-terminal sequence of the first ten resi-
dues of this enzyme was found to be identical to the rat 
pancreatic elastase-2 (EC 3.4.21.71) and the enzyme was 
called Ang II-forming elastase-2 of rat mesenteric arterial 
bed perfusate. The sequencing of cDNAs for pancreatic 
elastase-2 and rat mesenteric arterial bed showed that 
they were identical (51). The sequences were also identi-
cal to that previously published by MacDonald et al. (52) 
for elastase-2 from rat pancreas. At present, elastase-2 is 
the only representative of this family of proteases that is 
secreted outside the digestive tract and is involved in Ang 
II generation. The mRNA for elastase-2 was also detected 
in other tissues, such as lungs, heart, kidney, liver, spleen, 
and carotid artery (38). 
A notable feature of elastase-2 as an Ang I-converting 
enzyme is that it does not destroy the Ang II product formed 
by only one cleavage (Figure 2) (34). This characteristic 
is shared with some chymases, such as human (27), 
baboon (43), and dog (53) chymases, but not with the 
Figure 2. Hydrolysis of angiotensin I (Ang I) by the action of Ang II-forming en-
zyme purified from rat. Ang I (10 nmol) was incubated with 30 μg elastase-2 
(ELA-2) enzyme for 30 min at 37°C. The products of hydrolysis were separated by 
reversed-phase HPLC with an acetonitrile gradient.
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majority of rodent chymases, such as the rat and mouse, 
that are mainly Ang II-degrading enzymes (29,49,54). Rat 
and mouse elastase-2 has only Ang II-forming activity. Its 
catalytic activity for the conversion of Ang I to Ang II is high 
(Kcat/km = 42.5 mM/min). The fact that elastase-2 inter-
acts with [D-Pro11-Ala12]-Ang I and is sensitive to CH5450 
(35), both regarded as a selective substrate and inhibitor 
for human chymase, suggests that the formation of Ang 
II by chymases in vivo, particularly in the rat, may have 
been overestimated in previous studies addressing Ang 
II-forming alternative pathways. In addition, as described 
for tonin, elastase-2 can also generate Ang II directly from 
angiotensinogen (22,34,55). 
A functional role for elastase-2, as an alternative Ang 
II-generating pathway in the rat vasculature, was suggested 
by our laboratory. By using a conductance vessel (carotid) 
we demonstrated that ACE and elastase-2 are synergisti-
cally involved in the generation of Ang II from Ang I in 
physiological conditions (39). We recently demonstrated 
that chronic treatment of normotensive and spontaneously 
hypertensive rats with enalapril induces greater participation 
of serine proteases in the formation of Ang II from Ang I. 
This chymostatin-sensitive Ang II generation is markedly 
increased in the carotid arteries from hypertensive rats and 
the analysis of elastase-2 mRNA expression showed an 
increased elastase-2 message in carotid arteries of hyper-
tensive rats. It is interesting to note that increased expres-
sion of elastase-2 associated with chronic ACE inhibition 
is not restricted to the carotid artery, since similar results 
were observed in hearts of hypertensive rats, indicating that 
increased expression of elastase-2 upon ACE inhibition may 
be a widespread phenomenon (56,57). Our recent discovery 
of elastase-2 as an alternative Ang II-generating pathway in 
the vasculature indicates that this enzyme may be important 
in diseases such as arterial hypertension.
The current awareness of the functional complexity of 
the multifaceted, multicomponent RAS has been reinforced 
by the identification of different proteases that can process 
both Ang I and Ang II to generate active metabolites, which 
can trigger opposing biological responses and might play 
peculiar regulatory roles in the local RAS. The existence of 
other enzymes besides ACE generating Ang II, the so-called 
alternative pathways of Ang II generation, such as human 
chymase and rat elastase-2, suggests that these proteases 
may have a role in physiopathological conditions and may 
underlie the cardiovascular effects of ACE inhibitors.
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